Buy. DXCM's 85/100 Growth Compounder Score reflects sustained double-digit revenue growth in continuous glucose monitoring, a market with durable tailwinds from diabetes prevalence and insurance coverage expansion. Leadership alignment is solid (76.5/100) with founder-CEO Kevin Sayer retaining meaningful stake, though the vulnerability profile—driven by thin financial buffers and dependence on reimbursement policy—demands monitoring of cash flow and regulatory developments.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for DXCM:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 76/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates DXCM (DXCM) at 76/100 — a Hold — quality is solid but valuation or risk factors cap upside. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Buy. DXCM's 85/100 Growth Compounder Score reflects sustained double-digit revenue growth in continuous glucose monitoring, a market with durable tailwinds from diabetes prevalence and insurance coverage expansion. Leadership alignment
DXCM's current Stocky Verdict is 76/100, placing it in the "Buy" band. This composite combines a 85/100 Compounder score, 77/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for DXCM yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
DXCM scores 77/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
DXCM's Vulnerability Profile scores 100/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to DXCM.
Sign up free and unlock the full analysis on DXCM — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
Or jump straight to the interactive dashboard for DXCM in the app.
